Cargando…
Leukocyte Telomere Length as Potential Biomarker of HD Progression: A Follow-Up Study
The identification of biomarkers for neurodegenerative disorders such as Huntington’s disease (HD) is crucial for monitoring disease progression and therapeutic trial outcomes, especially in the pre-manifest disease stage (pre-HD). In a previous study, we observed that leukocyte telomere length (LTL...
Autores principales: | Scarabino, Daniela, Veneziano, Liana, Mantuano, Elide, Arisi, Ivan, Fiore, Alessia, Frontali, Marina, Corbo, Rosa Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654348/ https://www.ncbi.nlm.nih.gov/pubmed/36362235 http://dx.doi.org/10.3390/ijms232113449 |
Ejemplares similares
-
Leukocyte Telomere Length Variability as a Potential Biomarker in Patients with PolyQ Diseases
por: Scarabino, Daniela, et al.
Publicado: (2022) -
Can leukocyte telomere shortening be a possible biomarker to track Huntington’s disease progression?
por: Mantuano, Elide, et al.
Publicado: (2019) -
Analysis of the Association Between TERC and TERT Genetic Variation and Leukocyte Telomere Length and Human Lifespan—A Follow-Up Study
por: Scarabino, Daniela, et al.
Publicado: (2019) -
Leukocyte telomere length and plasma interleukin-1β and interleukin-18 levels in mild cognitive impairment and Alzheimer’s disease: new biomarkers for diagnosis and disease progression?
por: Corbo, Rosa Maria, et al.
Publicado: (2020) -
Molecular mechanism of Spinocerebellar Ataxia type 6: glutamine repeat disorder, channelopathy and transcriptional dysregulation. The multifaceted aspects of a single mutation
por: Giunti, Paola, et al.
Publicado: (2015)